Under one in 10 individuals eligible to benefit from weight-loss injections including Wegovy are able to get them, states the World Health Organization as it publishes its initial guidance on the drugs.
Given more than one billion individuals worldwide currently classified as obese, it is urging increased and just access to this class of drugs.
Per estimates, more than two billion could be obese by 2030 without intervention.
"The latest guidelines affirms that obesity is a lifelong illness that can be addressed with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key hurdles to broad availability to the treatments that can help people shift considerable body mass, says the organization.
Skinny Jab Supply Crisis
Despite the present best projected case, the manufacturing of these medications could only cover around 100 million people – under 10% of those who need them, per the WHO.
The recommendation encourages countries and companies to widen availability, through strategies like licensing agreements.
A patent on semaglutide – the primary component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Obesity Jabs Operate
GLP-1 drugs imitate a natural hormone to delay gastric emptying, suppress the appetite and enhance satiety so users consume fewer calories.
Patients usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies suggests users may regain a significant portion within a year of halting the drug, as their normal appetite come back.
To be carrying excess weight increases your chance for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects people in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
